Bectumomab is a monoclonal antibody that is primarily used in the field of oncology, specifically for the treatment of certain types of cancer. It is designed to target specific antigens present on the surface of cancer cells, facilitating the immune system's ability to recognize and destroy these cells. The CAS number 158318-63-9 identifies this substance uniquely in chemical databases. Bectumomab is often utilized in radioimmunotherapy, where it is conjugated with radioactive isotopes to deliver targeted radiation directly to tumor cells, minimizing damage to surrounding healthy tissue. Its mechanism of action involves binding to the target antigen, which can lead to various immune-mediated effects, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). As with many therapeutic antibodies, the efficacy and safety profile of Bectumomab are evaluated through clinical trials, and it may be associated with specific side effects related to immune response. Overall, Bectumomab represents a significant advancement in targeted cancer therapies, reflecting the growing trend towards personalized medicine in oncology.

Bectumomab

158318-63-9: Bectumomab is a monoclonal antibody that is primarily used in the field of oncology, specifically for the treatment of certain types of cancer. It is designed to target specific antigens present on the surface of cancer cells, facilitating the immune system's ability to recognize and destroy these cells. The CAS number 158318-63-9 identifies this substance uniquely in chemical databases. Bectumomab is often utilized in radioimmunotherapy, where it is conjugated with radioactive isotopes to deliver targeted radiation directly to tumor cells, minimizing damage to surrounding healthy tissue. Its mechanism of action involves binding to the target antigen, which can lead to various immune-mediated effects, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). As with many therapeutic antibodies, the efficacy and safety profile of Bectumomab are evaluated through clinical trials, and it may be associated with specific side effects related to immune response. Overall, Bectumomab represents a significant advancement in targeted cancer therapies, reflecting the growing trend towards personalized medicine in oncology.

<p>Bectumomab (IMMU-LL2) is a humanized IgG2a mAb targeting CD22, used in imaging and staging non-Hodgkin's lymphoma.</p>

Anti-CD22 Fab' fragment monoclonal antibody

CAS 158318-63-9

Bectumomab

Bectumomab

Ref: TM-T76920

Bectumomab

Ref: 3D-CLA1228